Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of IMR-687 in adults with beta-thalassemia
MOH_2020-07-27_009177Phase 2Recruiting
- Sponsor
- Imara Therapeutics
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tovinontrine in beta thalassemia and hemoglobin E beta thalassemia (HbE/β-thal) (3 arms), sponsored by Imara Therapeutics. Primary endpoint: Safety and tolerability. Started Jun 2020; status: recruiting.
02
Drugs
tovinontrine
03
Conditions
beta thalassemiahemoglobin E beta thalassemia (HbE/β-thal)
Beyond the preview
Go deeper on MOH_2020-07-27_009177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-27_009177.